A possible mechanism for the aglycemia-induced depression of glutamatergic excitation in the striatum.
We have studied the possible mechanisms underlying the decrease of excitatory transmission induced by glucose deprivation by using electrophysiological recordings in corticostriatal slices. Extracellular field potentials were recorded in the striatum after cortical stimulation; these potentials were progressively reduced by glucose deprivation. The reduction started 5 minutes after the onset of aglycemia. The field potential was fully suppressed after 40 minutes of glucose deprivation. After the washout of the aglycemic solution only a partial recovery was observed. Aglycemia also induced a delayed inward current during single-microelectrode voltage-clamp recordings from spiny neurons. This inward current was coupled with an increased membrane conductance. The A1 adenosine receptor antagonists, 8-cyclopentyl-1,3-dimethylxanthine (CPT, 1 micromol/L) and 1,3-dipropyl-8-cyclopentylxanthine (CPX, 300 nmol/L), significantly reduced the aglycemia-induced decrease of field potential amplitude. Moreover, in the presence of CPT and CPX, a full recovery of the field potential amplitude after the interruption of the aglycemic solution was observed. Conversely, these antagonists affected neither the inward current nor the underlying conductance increase produced by glucose deprivation. The ATP-sensitive potassium channel blockers glibenclamide (10 micromol/L) and glipizide (100 nmol/L) had no effect on the aglycemia-induced decrease of the field potential amplitude. We suggest that endogenous adenosine, but not ATP-dependent potassium channels, plays a significant role in the aglycemia-induced depression of excitatory transmission at corticostriatal synapses probably through a presynaptic mechanism. Moreover, adenosine is not involved in the postsynaptic changes induced by glucose deprivation in spiny striatal neurons.
Calabresi
P
P
Clinica Neurologica, Universita di Roma Tor Vergata, Dip. Sanita, Rome, Italy.
Centonze
D
D
Pisani
A
A
Bernardi
G
G
D000255:Adenosine Triphosphate / Q000494:pharmacology; D000818:Animals; D003342:Corpus Striatum / Q000503:physiopathology*; D004553:Electric Conductivity; D004594:Electrophysiology; D005947:Glucose / Q000008:administration & dosage; D018698:Glutamic Acid / Q000502:physiology*; D007003:Hypoglycemia / Q000503:physiopathology*; D008839:Microelectrodes; D026902:Potassium Channel Blockers; D058915:Purinergic P1 Receptor Antagonists; D051381:Rats; D017208:Rats, Wistar; D009435:Synaptic Transmission / Q000502:physiology; D013806:Theophylline / Q000031:analogs & derivatives / Q000494:pharmacology; D014970:Xanthines / Q000494:pharmacology
D026902:Potassium Channel Blockers; D058915:Purinergic P1 Receptor Antagonists; D014970:Xanthines; C053907:8-cyclopentyl-1,3-dimethylxanthine; D018698:Glutamic Acid; D000255:Adenosine Triphosphate; C051360:1,3-dipropyl-8-cyclopentylxanthine; D013806:Theophylline; D005947:Glucose